FRANKFORT, Ky., Oct. 22, 2014 (GLOBE NEWSWIRE) -- Farmers Capital Bank Corporation (Nasdaq:FFKT) (the "Company") reported net income of $4.1 million or $.49 per common share for the third quarter and $12.3 million or $1.44 per common share for the first nine months of 2014. Net income for the current quarter decreased $717 thousand or 14.9% compared with the current year second quarter, which represents a decrease of $.08 per common share. Compared to their respective year ago periods, net income increased $1.1 million or 35.3% for the third quarter and $1.9 million or 18.6% for the first nine months. On a per common share basis, net income increased $.15 or 44.1% and $.25 or 21.0% when compared with the prior-year three and nine month periods, respectively.
EINDHOVEN, The Netherlands, Oct. 23, 2014 (GLOBE NEWSWIRE) -- NXP Semiconductors N.V. (Nasdaq:NXPI) today reported financial results for the third quarter of 2014, ended September 28, 2014, and provided guidance for the fourth quarter of 2014.
LEAWOOD, Kan., Oct. 22, 2014 (GLOBE NEWSWIRE) -- Euronet Worldwide, Inc. ("Euronet" or the "Company") (Nasdaq:EEFT), a leading electronic payments provider, reports third quarter 2014 financial results.
LA JOLLA, Calif., Oct. 22, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to MN-001 (tipelukast) for treatment of idiopathic pulmonary fibrosis (IPF). Orphan-drug designation will provide MediciNova with seven years of marketing exclusivity for MN-001 (tipelukast) for the treatment of IPF if it is approved for this indication.
WASHINGTON, D.C., Oct. 22, 2014 (GLOBE NEWSWIRE) -- via PRWEB - The Alliance for Bangladesh Worker Safety announced today that it has contracted with the University of Texas Health Science Center at Houston to conduct an independent assessment of the Alliance basic fire safety training for garment factory workers in Bangladesh. The project team will be led by Dr. Hasanat Alamgir, a University of Texas (UT) School of Public Health associate professor of occupational health at the Program in Environmental and Occupational Health Sciences. The team will conduct a research study to yield valid and reliable results, collect data through randomized surveys and focus groups from workers, and ultimately deliver a detailed report on the effectiveness of the Alliance worker training. This report will help identify areas of improvement as the Alliance training programs continue and expand the in the coming years.
MARTINSRIED/MUNICH, Germany, Oct. 22, 2014 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) announced today that its collaborator Janssen Biotech, Inc. has initiated a phase 3 clinical trial in moderate to severe plaque-type psoriasis with the HuCAL antibody guselkumab (CNTO1959). The event triggered a clinical milestone payment to MorphoSys. Further financial details were not disclosed.
MARTINSRIED/MUNICH, Germany, Oct. 22, 2014 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX OTC: MPSYY) today announced that it is adjusting its EBIT guidance for the current year. MorphoSys now expects a negative EBIT in the range of EUR -5 million to EUR -8 million (from previously EUR -11 million to EUR -16 million). Reasons for the change are the now confirmed receipt of a milestone payment from Janssen, which directly affects the profit line, as well as a partial shift of proprietary development expenses to 2015. Revenues are now expected at the upper end of the previously communicated guidance range of EUR 58 million to EUR 63 million.
GlobeNewswire, a NASDAQ OMX company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.